Post by account_disabled on Feb 27, 2024 22:23:37 GMT -8
The catastrophic scenario that humanity experienced for almost two years, and that remains latent in countries like China and others, due to the pandemic, has driven the search for medical solutions such as vaccines or the most recent anti-COVID pill from Pfizer, since As the WHO states : the health emergency is not over.
With approximately 464 million cases and 6 million Changsha Mobile Number List deaths worldwide, COVID-19 as of March 2022, this disease continues to cause uncertainty and great inequalities.
However, in a show of Corporate Social Responsibility (CSR) , Pfizer has given 35 pharmaceutical companies the possibility of manufacturing and manufacturing a less expensive version of Paxlovid, a drug that helps in the fight against mild and medium symptoms of the disease. disease caused by coronavirus.
How does Pfizer's anti-COVID pill work?
Last year, Pfizer announced that it would release Paxlovid, an antiviral pill for the treatment of COVID-19, which according to the company is 89% effective in reducing the risk of hospitalization and death , since Of the patients, who took the pill within the first five days of having symptoms, only between 0.8% and 1.6% were hospitalized and there were no deaths.
The drug is being considered as a remedy that “could be prescribed as a home treatment to help reduce the severity of illness, hospitalizations and deaths, as well as the likelihood of infection after exposure, among adults,” he said. Pfizer when presenting it.
pfizer anti covid pill works
Pfizer's anti-COVID pill is made up of Nirmatrelvir and Ritonavir , two antivirals with protease inhibitors, an enzyme that breaks down the proteins of viruses and are usually used in HIV treatments.
Despite its effectiveness, Paxlovid has a problem: its production time, which can range from 6 to 8 months, this slowness is a factor in its arrival to those who require it.
Vaccination gap
According to the UN, the gap between rich and poor countries in population inoculation against COVID-19 remains unbalanced, despite the efforts of COVAX —an alliance that seeks to guarantee equitable access to vaccines, and which is part of its ACT Accelerator strategy – a global collaborative initiative to accelerate the development and production of COVID-19 tests, treatments and vaccines and ensure equitable access.
The unequal distribution of vaccines is not only a moral outrage, it is also economically and epidemiologically counterproductive. Some countries are racing to vaccinate their entire population, while other countries have nothing.
United Nations.
pfizer gap anti covid pill
The American continent is one of the regions where this inequality is latent. Recently, the director of the Pan American Health Organization (PAHO), Carissa F. Etienne, stated that 63% of people in Latin America and the Caribbean have already been vaccinated but with a widely uneven reach.
While 14 countries and territories have vaccinated 70% of their populations, the same number have failed to reach even 40% coverage.
Carissa F. Etienne, director of the Pan American Health Organization (PAHO).
For its part, the European Union has managed to vaccinate more than 70% of its population, and El País assures that some "organizations that advocate universal immunization report that there are more Europeans with the booster dose (204 million) than Africans with the complete guideline (151 million).
pfizer anti covid pill vaccine
With these big differences, it seems that the battle against this disease will continue to be less difficult for those who can pay more, although a recent action that will allow Pfizer's anti-COVID pill to be manufactured in other territories at a cheaper price could contribute. to those nations that do not enjoy privileges.
They will bring Pfizer's anti-COVID pill to more people
According to Reuters , thanks to an agreement between the Medicines Patent Pool (MPP) organization, dedicated to seeking access to health, and Pfizer, 35 companies will have the possibility of manufacturing Paxlovid, Pfizer's anti-COVID pill, to bring the treatment to 95 poor nations.
This agreement was approved last year , however, they have been working on the selection of the producers to whom the license will be given. Likewise, both the pharmaceutical company and the NGO assure that none of the chosen corporations will be able to produce significant supplies before end of the year.
With approximately 464 million cases and 6 million Changsha Mobile Number List deaths worldwide, COVID-19 as of March 2022, this disease continues to cause uncertainty and great inequalities.
However, in a show of Corporate Social Responsibility (CSR) , Pfizer has given 35 pharmaceutical companies the possibility of manufacturing and manufacturing a less expensive version of Paxlovid, a drug that helps in the fight against mild and medium symptoms of the disease. disease caused by coronavirus.
How does Pfizer's anti-COVID pill work?
Last year, Pfizer announced that it would release Paxlovid, an antiviral pill for the treatment of COVID-19, which according to the company is 89% effective in reducing the risk of hospitalization and death , since Of the patients, who took the pill within the first five days of having symptoms, only between 0.8% and 1.6% were hospitalized and there were no deaths.
The drug is being considered as a remedy that “could be prescribed as a home treatment to help reduce the severity of illness, hospitalizations and deaths, as well as the likelihood of infection after exposure, among adults,” he said. Pfizer when presenting it.
pfizer anti covid pill works
Pfizer's anti-COVID pill is made up of Nirmatrelvir and Ritonavir , two antivirals with protease inhibitors, an enzyme that breaks down the proteins of viruses and are usually used in HIV treatments.
Despite its effectiveness, Paxlovid has a problem: its production time, which can range from 6 to 8 months, this slowness is a factor in its arrival to those who require it.
Vaccination gap
According to the UN, the gap between rich and poor countries in population inoculation against COVID-19 remains unbalanced, despite the efforts of COVAX —an alliance that seeks to guarantee equitable access to vaccines, and which is part of its ACT Accelerator strategy – a global collaborative initiative to accelerate the development and production of COVID-19 tests, treatments and vaccines and ensure equitable access.
The unequal distribution of vaccines is not only a moral outrage, it is also economically and epidemiologically counterproductive. Some countries are racing to vaccinate their entire population, while other countries have nothing.
United Nations.
pfizer gap anti covid pill
The American continent is one of the regions where this inequality is latent. Recently, the director of the Pan American Health Organization (PAHO), Carissa F. Etienne, stated that 63% of people in Latin America and the Caribbean have already been vaccinated but with a widely uneven reach.
While 14 countries and territories have vaccinated 70% of their populations, the same number have failed to reach even 40% coverage.
Carissa F. Etienne, director of the Pan American Health Organization (PAHO).
For its part, the European Union has managed to vaccinate more than 70% of its population, and El País assures that some "organizations that advocate universal immunization report that there are more Europeans with the booster dose (204 million) than Africans with the complete guideline (151 million).
pfizer anti covid pill vaccine
With these big differences, it seems that the battle against this disease will continue to be less difficult for those who can pay more, although a recent action that will allow Pfizer's anti-COVID pill to be manufactured in other territories at a cheaper price could contribute. to those nations that do not enjoy privileges.
They will bring Pfizer's anti-COVID pill to more people
According to Reuters , thanks to an agreement between the Medicines Patent Pool (MPP) organization, dedicated to seeking access to health, and Pfizer, 35 companies will have the possibility of manufacturing Paxlovid, Pfizer's anti-COVID pill, to bring the treatment to 95 poor nations.
This agreement was approved last year , however, they have been working on the selection of the producers to whom the license will be given. Likewise, both the pharmaceutical company and the NGO assure that none of the chosen corporations will be able to produce significant supplies before end of the year.